# A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)

> **NCT03066778** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 453 (actual)

## Conditions studied

- Small Cell Lung Cancer (SCLC)

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Normal saline solution
- **DRUG:** Carboplatin
- **DRUG:** Cisplatin
- **DRUG:** Etoposide

## Key facts

- **NCT ID:** NCT03066778
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-02
- **Primary completion:** 2019-12-02
- **Final completion:** 2021-09-21
- **Target enrollment:** 453 (ACTUAL)
- **Last updated:** 2022-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03066778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03066778, "A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03066778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*